Title |
Elucidating the Function of the NF1 Tumor Suppressor and its Effector Pathways in
|
Institution |
BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA
|
Principal Investigator |
CICHOWSKI, KAREN
|
NCI Program Director |
Yassin
|
Cancer Activity |
Cancer Cell Biology
|
Division |
DCB
|
Funded Amount |
$276,167
|
Project Dates |
07/01/2005 - 05/31/2015
|
Fiscal Year |
2014
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Cancer (100.0%)
Neurofibromatosis (100.0%)
|
Melanoma (50.0%)
Nervous System (50.0%)
|
Research Type |
Cancer Initiation: Oncogenes and Tumor Suppressor Genes
|
Abstract |
DESCRIPTION (provided by applicant): Loss-of-function mutations in the NF1 tumor suppressor gene underlie the familial cancer syndrome neurofibromatosis type 1. More recently NF1 mutations have been detected in sporadic tumors, suggesting that NF1 plays an even broader role in human cancer. The overall goal of this application is to elucidate the molecular mechanisms by which NF1 inactivation promotes tumorigenesis. The NF1- encoded protein, neurofibromin, functions as a Ras-GTPase activating protein (RasGAP). Accordingly, deregulation of Ras contributes to NF1 development; however, the precise molecular function of neurofibromin remains unclear. Thus the goals of this application are to 1) establish a new function of neurofibromin and define a novel effector pathway involved in tumorigenesis and 2) systematically define the NF1 tumor suppressor network as it relates to the Ras pathway. An additional goal is to elucidate how NF1 mutations participate in a previously unrecognized sporadic tumor-type. To accomplish these aims we will be using cell biological, genetic, biochemical and some mouse modeling approaches. Collectively these studies will not only provide a comprehensive understanding of how neurofibromin regulates the Ras pathway, should identify the most critical therapeutic targets in this pathway, which may ultimately impact therapeutic development and treatments. |